Tumour Therapy with Radiolabelled Antibodies


The promise of radiolabelled immunoglobulin therapy (RIT) for selective, patient friendly, cancer treatment has not yet been fulfilled. Only patients with haematological malignancies show sizable response rates after RIT. With solid tumours, intravenous administration of radiolabelled antibodies does not provide sufficient tumour targeting. However… (More)
DOI: 10.2165/00063030-199810040-00003

18 Figures and Tables


  • Presentations referencing similar topics